Abstracts
PCN8 COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND ASSOCIATED COSTS AMONG PATIENTS RECEIVING SARGRAMOSTIM, FILGRASTIM, AND PEGFILGRASTIM FOR CHEMOTHERAPY-INDUCED NEUTROPENIA
Duh MS 1 , Toy EL 2 , Vekeman F 3 , Laliberte F 3 , Dority BL 2 , Perlman D 2 , Barghout V 4 , Heaney ML 5 1 Analysis Group, Inc., Boston, MA, USA, 2 Analysis Group, Inc., Lakewood, CO, USA, 3 Groupe d'analyse, Ltee, Montréal, QC, Canada, 4 Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 5 Memorial Sloan-Kettering Cancer Center, New York, NY, USA OBJECTIVES: Myelosuppressive chemotherapy can lead to neutropenia and increase infection risk. Myeloid growth factors are commonly used to treat/prevent neutropenia. Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF). Unlike fi lgrastim and pegfi lgrastim, which are granulocyte colony-stimulating factors (G-CSFs), sargramostim activates a broader range of myeloid lineage-derived cells. Therefore, GM-CSF might reduce infection risk more than G-CSFs. This study compared real-world infection-related hospitalization rates and costs in patients using G/GM-CSF for chemotherapy-induced neutropenia. METHODS: This retrospective matched-cohort study analyzed nationally-representative health insurance claims in the US in 2000-2007. The sample population included patients who received chemotherapy and G/GM-CSF. G/GM-CSF treatment episodes began with the fi rst administration of G/GM-CSF and ended when a subsequent administration was 28 days after a prior administration. Sargramostim patients were matched 1:1 with fi lgrastim and pegfi lgrastim patients based on gender and birth year. Outcomes included infection-related hospitalization rates and the associated costs. Hospitalization rates were analyzed using univariate and multivariate Poisson methods; covariates included myelosuppressive agents received, tumor type, anemia, and comorbidities. RESULTS: A total of 990 sargramostim-fi lgrastim and 982 sargramostim-pegfi lgrastim pairs were analyzed. Cohorts had similar baseline characteristics, though differences were observed in the fraction of patients with a neutropenia diagnosis (sargramostim 65%, fi lgrastim 57%, pegfi lgrastim 45%) and who received myelosuppressive agents (sar-gramostim 54%, fi lgrastim 48%, pegfi lgrastim 77%). Sargramostim patients experienced infection-related hospitalizations about half as often as fi lgrastim (p 0.04) or pegfi lgrastim (p 0.06) patients. Multivariate analyses adjusted for confounding factors and found that sargramostim patients were 56% less likely to have infectionrelated hospitalizations compared to fi lgrastim and pegfi lgrastim patients (p 0.03 for both). Infection-related hospitalization costs for sargramostim patients were $728/ patient/month and $226/patient/month less compared to fi lgrastim (p 0.04) and pegfi lgrastim patients (p 0.01), respectively. CONCLUSIONS: Among patients with chemotherapy-induced neutropenia, sargramostim use is associated with reduced risk of infection-related hospitalization and lower associated costs compared to fi lgrastim or pegfi lgrastim.
PCN9 SYSTEMATIC LITERATURE REVIEW TO ADDRESS BREAST CANCER ISSUES IN LOW-AND MIDDLE-INCOMES COUNTRIES FROM 1990-2008
Ekwueme DU 1 , Coughlin SS 2 , Miller J 1 , Bobo J 3 , Justen E 4 1 CDC, Atlanta, GA, USA, 2 Department of Veterans Affairs, Washington, DC, DC, USA, 3 Battelle, Centers for Public Health Research and Evaluation, Seattle, WA, USA, 4 CDC Foundation, Atlanta, GA, USA OBJECTIVES: Breast cancer prevention and control in low-and middle-income countries (LMCs) are critical emerging issues. Most LMCs lack suffi cient resources for screening, early detection, and treatment of breast cancer. However, little is known about what works to reduce the burden of breast cancer in low-resource settings or how best to maximize public health interventions. The purpose of this study was to assemble a knowledge base of studies in LMCs on breast cancer prevention, early detection, treatment, and palliative care that address issues of equity, access, and costs.
METHODS:
We conducted a systematic literature search via PUBMED and other computerized electronic databases. We classifi ed each citation as relevant, peripherally relevant, not relevant, or unknown and maximized the criteria by using free-text words and medical subject headings. All citations identifi ed were independently reviewed by three members of the research team. Relevant studies were selected if they met inclusion criteria: published in English or Spanish between January 1, 1990 and April 30, 2008. RESULTS: A total of 1907 citations were identifi ed, of which, 53.2% were excluded as "not relevant;" 27.1% were considered likely to be "relevant"; 5.5% were coded "peripherally relevant"; and 6.0% were "unknown". All relevant articles (516) coming from 60 LMCs met the inclusion criteria and were abstracted. We found 80 articles on East Asia/Pacifi c countries; 82 on Europe/Central Asia countries; 76 on Latin American/Caribbean countries; 64 on Middle East/North Africa countries; 100 on South Asia countries; 71 on Sub-Saharan Africa countries; and 43 articles with no region-specifi c focus. We identifi ed three articles on palliation and end-of-life care and a small number of articles reported cost data or economic analyses. CONCLUSIONS: The review contains a wealth of practical information that would be extremely useful to the myriad of clinicians and public health professionals working to prevent and treat breast cancer in LMCs.
PCN10 LUNG CANCER IN THE CHINESE PASSIVE SMOKING POPULATIONS
Wang L g 1 , Li Y 2 1 Sichuan University, Chengdu, Sichuan, China, 2 West China Hospital, Sichuan University, Chengdu, China OBJECTIVES: Worldwide, the association of passive smoking with development of lung cancer has been ascertained. However, it remains unknown of the magnitude of the association in the Chinese population. We thus systematically reviewed the published studies worldwide. METHODS: We searched Medline, EMBASE, and three other Chinese databases from their inception to June 30, 2008. We included casecontrol and cohort studies that investigated the association of passive smoking with lung cancer, and that provided data on the magnitude of the association. Two reviewers screened the eligibility, assessed the extent of the bias, and extracted data independently. We obtained the unadjusted and adjusted estimates of studies. We pooled the trial data using the random-effect model and explored the heterogeneity by the pre-specifi ed variables. RESULTS: We included 20 studies (n 88,379). One was cohort study (n 72,829) and 19 case-control studies (cumulative cases: 5977, and controls: 9573). Passive smoking increase the risk of lung cancer by 25% (OR 1.25, 95%CI 1.03 to 1.47). Pooling of adjusted estimates of 10 case-control studies (2704 cases and 3495 controls) showed that the risk of lung cancer increased by 95% (1.95, 1.49 to 2.55). In female life-long non-smokers, the passive smoking increased the risk of lung cancer by 77% (1.77, 1.22 to 2.58, n 5685), and increased the risk of squamous cell carcinoma and adenocarcinoma of female non-smokers by 99% (1.99, 1.19 to 3.33) and 7% (1.05, 0.45 to 2.51). Because of the limited data, no signifi cant dose-response relationship was found between the risk of lung cancer and the exposure amounts, durations and the initiating age. CONCLUSIONS: The increased risk of lung cancer associated with passive smoking in the Chinese population has been ascertained. Passive smoking has a strong association with squamous cell carcinoma.
PCN11 LUNG CANCER IN THE CHINESE SMOKING POPULATION
Wang L g 1 , Li Y 2 1 Sichuan University, Chengdu, Sichuan, China, 2 West China Hospital, Sichuan University, Chengdu, China OBJECTIVES: Worldwide, the association of smoking with development of lung cancer has been ascertained. However, it remains unknown of the magnitude of the association in the Chinese population. We thus systematically reviewed the published
